Descripción del proyecto
Una tecnología de ingeniería celular asequible
La modificación de las células inmunitarias por ingeniería para combatir el cáncer ha obtenido prometedores resultados y constituye una alternativa terapéutica cuando fracasa la quimioterapia. Sin embargo, los tratamientos celulares son caros de producir, por lo que se requieren métodos de ingeniería más rentables. El objetivo del proyecto SOLUPORE, financiado con fondos europeos, es producir la siguiente generación de tratamientos celulares con un menor coste. La plataforma de SOLUPORE no utiliza vectores víricos, sino una nueva tecnología de administración de ARNm, ADN o proteínas a las células NK y los linfocitos T que permite conservar una alta funcionalidad y viabilidad celulares. La simplicidad del método de SOLUPORE hace que sea fácil de utilizar y apto para la producción de inmunoterapias.
Objetivo
There is encouraging news for cancer patients, a new treatment, cell immunotherapy, has been delivering spectacular
clinical results and is a game changer because it is an entirely new way of treating cancer. Cancer immunotherapy, in which
a patient’s own immune cells are ‘armed’ by cell engineering to target and kill cancer cells, gives levels of complete response
in patients. The first cell immunotherapy drug was approved in August 2017 at a price of $475,000 per treatment. To bring
these life-changing treatments to patients and relieve the European and global healthcare burden they must become
available at affordable costs. The one thing worse than failure is unaffordable success and the challenge with these
treatments is the complex and high-cost of manufacturing. Current cell engineering methods are very expensive to
manufacture. Avectas has developed Solupore, a cell engineering technology, which delivers cargo to cells and plays a
critical role in the manufacturing process. The technology works by temporarily making the cell membrane permeable and
allowing cargo into the cell. Crucially, cell health and functionality are preserved while there is a significant improvement on
the process time and costs. Avectas has demonstrated that the pilot system can successfully deliver clinically relevant cargo
to T cells. During this project, Avectas will scale and align Solupore to regulatory compliance enabling us to commercialise
it. The emerging and fast-growing cell immunotherapy market is set to be worth $20bn in 2020, with cell manufacturing
representing $5bn. Commercialisation of Solupore will take 1% of the €5bn market share by 2024 and will generate global
revenues for Avectas, building value for the company and creating highly skilled jobs which will result in a high-value,
knowledge-based EU company. There will be substantial European and global socio-economic impact on cancer patients
living longer, better quality lives.
Ámbito científico
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SMEInst-2018-2020-2
Régimen de financiación
SME-2 - SME instrument phase 2Coordinador
W23 F2H6 Kildare
Irlanda
Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención.